NCT05906524 2024-01-10KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid TumorsShanghai Kanda Biotechnology Co., Ltd.Phase 1/2 Unknown85 enrolled